AxoGen, Inc. revised revenue guidance for the full year of 2023. The company now expects full-year 2023 revenue to be at the high end of the $154 million to $159 million guidance range provided earlier in the year. This represents annual growth of approximately 15%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 USD | -3.27% | +8.45% | -0.44% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.44% | 299M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+0.53% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen, Inc. Revises Revenue Guidance for the Full Year of 2023